OBJECTIVE

To investigate whether parental family history of diabetes influences cardiovascular outcomes in type 2 diabetes.

RESEARCH DESIGN AND METHODS

We studied 1,294 type 2 diabetic patients (mean age 64.1 years, 51.2% female) recruited to a community-based cohort study from 1993 to 1996 and followed until mid-2006. A data linkage system assessed all-cause and cardiac mortality, incident myocardial infarction, and stroke. Cox proportional hazards modeling was used to determine the influence of maternal or paternal family history on these outcomes.

RESULTS

A maternal family history of diabetes was reported by 20.4% of the cohort, 8.3% reported paternal family history, and 2.0% reported both parents affected. Maternal and paternal family history was associated with earlier age of diabetes onset, and maternal family history was associated with worse glycemic control. For all patients, maternal family history was significantly associated with reduced risk of all-cause mortality and cardiac mortality. When analyzed by sex, maternal family history had no effect on male patients, whereas female patients with diabetic mothers had significantly reduced hazard ratios for death from all causes (0.63 [95% CI 0.41–0.96]; P = 0.033), for death from cardiac causes (0.32 [0.14–0.72]; P = 0.006), and for first myocardial infarction (0.45 [0.26–0.76]; P = 0.003). Paternal family history status was not associated with these outcomes.

CONCLUSIONS

A maternal family history of diabetes confers relative protection against cardiovascular disease in female patients but not in male patients with type 2 diabetes. Paternal family history is associated with risks equivalent to those without a family history of diabetes. Some of the clinical heterogeneity of type 2 diabetes is related to maternal transmission effects with differential impact on male and female patients.

The complex etiology of type 2 diabetes involves both genetic components and environmental exposures. In type 2 diabetes, there is a well documented association between a family history of the disease and its development (1,2). Maternal and paternal family histories of diabetes are both associated with an earlier age of onset (2,4), and this effect is more marked when multiple family members are affected (5). In addition, intrauterine exposure to diabetes increases the risk of diabetes in offspring (6), which may help explain the reported excess maternal transmission (7,8).

Patients with familial diabetes have relatively poor glycemic control, but few other clinical differences have been reported (4,5,9,10). An early age of onset and poor glycemic control would both be expected to have a negative impact on the development of chronic complications, but no such longitudinal data have been published. In the present study, we examined relationships among parental diabetes and important clinical outcomes in type 2 diabetes, including incident coronary heart disease (CHD) and all-cause and cardiac mortality in a large community-based sample of patients with type 2 diabetes. We hypothesized that familial diabetes would indicate worse clinical outcomes. We investigated potential relationships in male and female patients separately, given the known differences in CHD incidence between men and women with diabetes (11).

The present sample comprised all participants with type 2 diabetes enrolled in the Fremantle Diabetes Study (FDS), a longitudinal observational study conducted from a postcode-defined urban Australian community of 120,097 people. Descriptions of recruitment, sample characteristics including classification of diabetes type, and details of nonrecruited patients have been published previously (12,13). Of 2,258 diabetic patients identified between 1993 and 1996, 1,426 (63%) were recruited and 1,294 had type 2 diabetes. The study protocol was approved by the Fremantle Hospital Human Rights Committee, and all subjects gave informed consent before participation.

Clinical assessment

Each participant underwent a comprehensive assessment at FDS entry that comprised 1) a standard questionnaire including questions on diabetes symptoms at onset, self–glucose monitoring, attendance at diabetes education/dietitian sessions, lifestyle factors, education, self-assessed ethnicity, fluency with English, and knowledge of diabetes (12); 2) a detailed physical examination; and 3) the provision of fasting blood and urine samples for automated biochemical tests performed in a single laboratory. As part of 1) above, all participants were asked to provide details of relatives with known diabetes (including a specific enquiry as to the status of mother, father, grandparents, son, daughter, grandchildren, brother, sister, uncle, aunt, and other) and their respective diabetes treatment status (whether insulin or tablet/diet treated).

Complications were identified using standard definitions (13). Peripheral neuropathy was defined as a score >2 of 8 on the Michigan Neuropathy Screening Instrument clinical portion. Retinopathy was taken as any grade detected by direct/indirect ophthalmoscopy and/or ophthalmologist assessment. Nephropathy was defined as a first-morning urinary albumin-to-creatinine ratio ≥3.0 mg/mmol. Self-reported stroke/transient ischemic attack were amalgamated with prior hospitalizations to define baseline cerebrovascular disease status. Patients were classified as having CHD if there was a self-reported history of or hospitalization for myocardial infarction, angina, revascularization, or angioplasty. Peripheral arterial disease was considered to be present when the ankle-to-brachial index was ≤0.90 or by the presence of a diabetes-related amputation.

Incident cardiovascular disease and mortality

The Hospital Morbidity Data System records all public and private hospital separations in Western Australia and, together with the death register, forms part of the Western Australia Data Linkage System (WADLS) (14). The FDS database was linked with the WADLS to provide morbidity/mortality data from 1 January 1993 until the end of June 2006. Hospitalizations for CHD and cerebrovascular disease were extracted from WADLS to calculate prevalent and incident myocardial infarctions and strokes. The causes of death were reviewed independently by two of the authors (D.G.B. and T.M.E.D.) and classified as being due to cardiac causes or not under the system used in the UK Prospective Diabetes Study (15). When there was disagreement between raters, a final consensus decision was reached.

Statistical methods

Pancreatic β-cell function and insulin sensitivity were estimated from fasting serum glucose (FSG) and serum insulin concentrations using homeostasis model assessment (16). All data were analyzed using SPSS for Windows (version 14.0.2). Because GHb, FSG, serum triglycerides, urinary albumin-to-creatinine ratio, insulin sensitivity, and pancreatic β-cell function were not normally distributed, they were log-transformed before analysis. Data are reported as means ± SD, geometric mean (SD range), medians (interquartile range), or percentages. ANOVA and Fisher's exact tests were used to test equality of means for normally distributed continuous and categorical variables, respectively. Variables with a nonparametric distribution were analyzed using the Kruskal-Wallis test. If differences were detected, pairwise comparison with a Student t test, Fisher exact test, or Mann-Whitney test was undertaken. Multivariate linear regression analysis was used to investigate effects on glycemic and blood pressure control after appropriate adjustment. Cox proportional hazards modeling (with forward conditional, variable entry, and removal at P < 0.05 and > 0.10, respectively) was used to determine independent predictors of all-cause mortality, cardiac mortality, first-time incident myocardial infarction, and first incident stroke (subjects with prior events were excluded from relevant models). All clinically plausible variables were considered for entry into the models before family history status was entered.

Baseline sample characteristics

The patient sample was aged 64.1 ± 11.3 years and 51.2% were women. A parental family history of diabetes was reported by 397 patients (30.7%), of whom 264 (20.4%) had a maternal family history, 107 (8.3%) had a paternal family history, and 26 (2.0%) had both parents affected (Table 1). Diabetes onset occurred at a significantly younger age in patients with parental diabetes. At the time of baseline assessment, they were also younger but had duration of diabetes similar to that of patients without a family history. Patients with a maternal family history had significantly higher FSG and GHb levels. Systolic blood pressure was lower with both maternal and paternal family histories.

Table 1

Demographic and baseline clinical characteristics and subsequent crude mortality rates of the sample by parental family history

Family history
P
NoMaternalPaternalBoth
n 897 264 107 26  
Age (years) 65.5 ± 10.8 61.4 ± 11.7 60.0 ± 11.5 58.0 ± 11.8 <0.001 
Age at diagnosis (years) 59.4 ± 11.1 55.6 ± 11.8 53.1 ± 12.5 51.8 ± 13.8 <0.001 
Diabetes duration (years) 4.0 [1.0–9.0] 4.0 [0.9–9.0] 4.0 [0.9–10.0] 4.0 [0.3–8.5] 0.99 
Male sex (%) 50.2 42.8 53.3 42.3 0.12 
Ethnic background (%)      
    Anglo-Celt 65.6 56.1 63.6 57.7  
    Southern European 16.7 22.7 20.6 23.1  
    Other European 8.7 9.5 6.5 0.0 NV 
    Asian 2.7 2.7 5.6 19.2  
    Mixed/other 5.2 6.4 2.8 0.0  
    Indigenous 1.1 2.7 0.9 0.0  
BMI (kg/m229.3 ± 5.4 30.4 ± 5.5 30.0 ± 5.3 29.6 ± 5.4 0.019 
Waist (% overweight/obese) 84.2 92.7 87.6 80.8 0.002 
Systolic blood pressure (mmHg) 152 ± 24 148 ± 22 147 ± 21 146 ± 23 0.009 
Diastolic blood pressure (mmHg) 81 ± 12 80 ± 10 80 ± 10 77 ± 8 0.38 
Fasting glucose (mmol/l) 8.2 [6.8–10.6] 8.9 [7.2–11.7] 8.4 [6.6–10.5] 8.9 [6.9–10.9] 0.013 
GHb (%) 7.3 [6.3–8.7] 7.9[6.7–9.2] 7.2 [6.4–8.7] 8.0 [6.6–8.9] 0.001 
Diabetes treatment (%)      
    Diet alone 32.0 27.3 42.1 38.5  
    Oral agents 55.3 61.0 49.5 57.7 0.10 
    Insulin (± oral agents) 12.7 11.7 8.4 3.8  
Total cholesterol (mmol/l) 5.5 ± 1.2 5.5 ± 1.0 5.5 ± 1.0 5.5 ± 1.2 0.97 
HDL cholesterol (mmol/l) 1.06 ± 0.33 1.05 ± 0.30 1.08 ± 0.35 1.10 ± 0.33 0.80 
Serum triglyceride (mmol/l) 1.9 (1.1–3.4) 1.9 (1.1–3.2) 2.0 (1.2–3.3) 1.7 (1.0–2.9) 0.72 
Cerebrovascular disease (%) 11.6 7.2 6.5 3.8 0.08 
CHD (%) 29.1 25.8 19.6 26.9 0.18 
Peripheral arterial disease (%) 30.0 30.3 24.5 15.4 0.28 
Retinopathy (%) 16.0 18.4 17.8 4.0 0.17 
Neuropathy (%) 33.7 26.3* 23.3* 12.0* 0.005 
Albumin-to-creatinine ratio (mg/mmol) 3.2 (0.7–13.7) 3.2 (0.8–13.1) 3.0 (0.5–16.7) 1.7 (0.6–4.7) 0.19 
Smoking status (%)      
    Never smoked 45.1 46.9 33.3 52.0  
    Former smoker 39.9 37.0 51.4 40.0 0.20 
    Current smoker 15.0 16.0 15.2 8.0  
All-cause mortality (%) 41.9 29.5 34.0 11.5 <0.001 
Cardiac mortality (%) 17.9 8.7 10.4 7.7 0.001 
Family history
P
NoMaternalPaternalBoth
n 897 264 107 26  
Age (years) 65.5 ± 10.8 61.4 ± 11.7 60.0 ± 11.5 58.0 ± 11.8 <0.001 
Age at diagnosis (years) 59.4 ± 11.1 55.6 ± 11.8 53.1 ± 12.5 51.8 ± 13.8 <0.001 
Diabetes duration (years) 4.0 [1.0–9.0] 4.0 [0.9–9.0] 4.0 [0.9–10.0] 4.0 [0.3–8.5] 0.99 
Male sex (%) 50.2 42.8 53.3 42.3 0.12 
Ethnic background (%)      
    Anglo-Celt 65.6 56.1 63.6 57.7  
    Southern European 16.7 22.7 20.6 23.1  
    Other European 8.7 9.5 6.5 0.0 NV 
    Asian 2.7 2.7 5.6 19.2  
    Mixed/other 5.2 6.4 2.8 0.0  
    Indigenous 1.1 2.7 0.9 0.0  
BMI (kg/m229.3 ± 5.4 30.4 ± 5.5 30.0 ± 5.3 29.6 ± 5.4 0.019 
Waist (% overweight/obese) 84.2 92.7 87.6 80.8 0.002 
Systolic blood pressure (mmHg) 152 ± 24 148 ± 22 147 ± 21 146 ± 23 0.009 
Diastolic blood pressure (mmHg) 81 ± 12 80 ± 10 80 ± 10 77 ± 8 0.38 
Fasting glucose (mmol/l) 8.2 [6.8–10.6] 8.9 [7.2–11.7] 8.4 [6.6–10.5] 8.9 [6.9–10.9] 0.013 
GHb (%) 7.3 [6.3–8.7] 7.9[6.7–9.2] 7.2 [6.4–8.7] 8.0 [6.6–8.9] 0.001 
Diabetes treatment (%)      
    Diet alone 32.0 27.3 42.1 38.5  
    Oral agents 55.3 61.0 49.5 57.7 0.10 
    Insulin (± oral agents) 12.7 11.7 8.4 3.8  
Total cholesterol (mmol/l) 5.5 ± 1.2 5.5 ± 1.0 5.5 ± 1.0 5.5 ± 1.2 0.97 
HDL cholesterol (mmol/l) 1.06 ± 0.33 1.05 ± 0.30 1.08 ± 0.35 1.10 ± 0.33 0.80 
Serum triglyceride (mmol/l) 1.9 (1.1–3.4) 1.9 (1.1–3.2) 2.0 (1.2–3.3) 1.7 (1.0–2.9) 0.72 
Cerebrovascular disease (%) 11.6 7.2 6.5 3.8 0.08 
CHD (%) 29.1 25.8 19.6 26.9 0.18 
Peripheral arterial disease (%) 30.0 30.3 24.5 15.4 0.28 
Retinopathy (%) 16.0 18.4 17.8 4.0 0.17 
Neuropathy (%) 33.7 26.3* 23.3* 12.0* 0.005 
Albumin-to-creatinine ratio (mg/mmol) 3.2 (0.7–13.7) 3.2 (0.8–13.1) 3.0 (0.5–16.7) 1.7 (0.6–4.7) 0.19 
Smoking status (%)      
    Never smoked 45.1 46.9 33.3 52.0  
    Former smoker 39.9 37.0 51.4 40.0 0.20 
    Current smoker 15.0 16.0 15.2 8.0  
All-cause mortality (%) 41.9 29.5 34.0 11.5 <0.001 
Cardiac mortality (%) 17.9 8.7 10.4 7.7 0.001 

Data are means ± SD, geometric means (SD range), medians [interquartile range], or %.

*P < 0.05;

P < 0.01 compared with no family history. NV, not valid.

After adjustment for age, diabetes duration, and treatment type, both FSG and GHb remained significantly higher with maternal family history [β ln(FSG) 0.05 (95% CI 0.01–0.09) mmol/l; P = 0.017 and ln(GHb) 0.05% (0.02–0.07); P = 0.001], but not with a paternal family history (P ≥ 0.39). After adjustment for age, no significant difference in systolic blood pressure levels was seen with maternal or paternal family histories. There were no differences by family history in proportions with GAD antibody positivity, pancreatic β-cell function, or insulin sensitivity, exercise levels, alcohol intake, or proportions taking blood pressure–lowering or lipid-lowering medications (data not shown).

Family history, mortality, myocardial infarction, and stroke

By the end of June 2006, crude all-cause mortality rates were significantly lower in patients with maternal and paternal family histories (Table 1). In Cox regression models (Table 2), we examined the effect of family history unadjusted (model 1), after adjustment for age and sex (where appropriate, model 2), and after adjustment for identified relevant variables (model 3, variables listed in supplementary Table 1, available in an online appendix at http://care.diabetesjournals.org/cgi/content/full/dc10-0147/DC1). In adjusted models, maternal or paternal family history was entered into the most parsimonious model to assess whether either was an independent determinant of outcome. For all patients, maternal family history was associated with a significantly reduced risk of death from all causes and from cardiac causes, whereas there was a trend toward a reduction in the risk of incident myocardial infarction (Table 2). When analyzed by sex, the protective effect of maternal family history on all-cause and cardiac mortality was only significant in female patients and was significant for incident myocardial infarction in women. Paternal family history was not associated with differences in clinical outcomes.

Table 2

Hazard ratios for clinical outcomes in patients with type 2 diabetes by parental history

No family history
Family history
Log-rank P valueHazard ratios (95% CI)
No. patientsNo. eventsAbsolute risk*No. patientsNo. eventsAbsolute risk*
All patients: maternal history         
    All-cause mortality         
        Model 1 1,001 410 43.1 290 81 26.4 <0.001 0.60 (0.48–0.77) 
        Model 2        0.81 (0.64–1.03) 
        Model 3§        0.69 (0.52–0.92) 
    Cardiac mortality         
        Model 1 1,001 172 18.1 290 25 8.2 <0.001 0.45 (0.30–0.69) 
        Model 2        0.61 (0.40–0.93) 
        Model 3§        0.50 (0.31–0.82) 
    Myocardial infarction         
        Model 1 977 227 25.6 281 51 17.9 0.023 0.70 (0.52–0.95) 
        Model 2        0.91 (0.67–1.24) 
        Model 3§        0.73 (0.52–1.03) 
    Stroke         
        Model 1 998 106 11.5 290 26 8.6 0.19 0.75 (0.49–1.15) 
        Model 2        1.00 (0.65–1.54) 
        Model 3§        0.73 (0.45–1.20) 
All patients: paternal history         
    All-cause mortality         
        Model 1 1,159 452 40.3 132 39 28.8 0.039 0.71 (0.51–0.98) 
        Model 2        0.92 (0.66–1.28) 
        Model 3§        1.06 (0.73–1.54) 
    Cardiac mortality         
        Model 1 1,159 184 16.4 132 13 9.6 0.06 0.59 (0.33–1.03) 
        Model 2        0.76 (0.43–1.34) 
        Model 3§        0.96 (0.52–1.78) 
    Myocardial infarction         
        Model 1 1,128 258 24.7 130 20 15.6 0.049 0.64 (0.40–1.00) 
        Model 2        0.79 (0.50–1.25) 
        Model 3§        0.98 (0.60–1.61) 
    Stroke         
        Model 1 1,156 120 11.0 132 12 9.0 0.50 0.81 (0.45–1.47) 
        Model 2        1.10 (0.61–2.00) 
        Model 3§        1.15 (0.60–2.21) 
Women: maternal history         
    All-cause mortality         
        Model 1 495 179 36.9 166 41 22.8 0.004 0.61 (0.44–0.86) 
        Model 2        0.81 (0.58–1.14) 
        Model 3§        0.63 (0.41–0.96) 
    Cardiac mortality         
        Model 1 495 77 15.9 166 10 5.6 0.001 0.35 (0.18–0.68) 
        Model 2        0.47 (0.24–0.91) 
        Model 3§        0.32 (0.14–0.72) 
    Myocardial infarction         
        Model 1 485 104 22.6 161 23 13.7 0.029 0.61 (0.39–0.96) 
        Model 2        0.83 (0.53–1.31) 
        Model 3§        0.45 (0.26–0.76) 
    Stroke         
        Model 1 495 52 11.0 166 14 7.9 0.27 0.72 (0.40–1.30) 
        Model 2        0.93 (0.51–1.67) 
        Model 3§        0.73 (0.40–1.36) 
Women: paternal history         
    All-cause mortality         
        Model 1 597 206 34.5 64 14 20.4 0.047 0.58 (0.34–1.00) 
        Model 2        0.82 (0.48–1.42) 
        Model 3§        1.20 (0.64–2.25) 
    Cardiac mortality         
        Model 1 597 83 13.9 64 5.8 0.08 0.42 (0.15–1.14) 
        Model 2        0.60 (0.22–1.65) 
        Model 3§        0.79 (0.25–2.56) 
    Myocardial infarction         
        Model 1 583 121 21.6 63 9.0 0.032 0.42 (0.19–0.95) 
        Model 2        0.59 (0.26–1.34) 
        Model 3§        0.62 (0.25–1.52) 
    Stroke         
        Model 1 597 64 11.0 64 2.9 0.045 0.26 (0.06–1.07) 
        Model 2        0.37 (0.09–1.50) 
        Model 3§        0.40 (0.10–1.63) 
Men: maternal history         
    All-cause mortality         
        Model 1 506 231 49.6 124 40 31.5 0.006 0.63 (0.45–0.88) 
        Model 2        0.80 (0.57–1.12) 
        Model 3§        0.78 (0.53–1.14) 
    Cardiac mortality         
        Model 1 506 95 20.4 124 15 11.8 0.044 0.58 (0.33–0.99) 
        Model 2        0.74 (0.43–1.29) 
        Model 3§        0.70 (0.39–1.27) 
    Myocardial infarction         
        Model 1 492 123 28.8 120 28 23.9 0.40 0.84 (0.56–1.26) 
        Model 2        0.99 (0.65–1.50) 
        Model 3§        0.92 (0.60–1.42) 
    Stroke         
        Model 1 503 54 12.0 124 12 9.6 0.48 0.80 (0.43–1.49) 
        Model 2        1.07 (0.57–2.01) 
        Model 3§        0.90 (0.47–1.75) 
Men: paternal history         
    All-cause mortality         
        Model 1 562 246 46.7 68 25 37.5 0.30 0.80 (0.53–1.21) 
        Model 2        0.96 (0.63–1.46) 
        Model 3§        1.03 (0.64–1.66) 
    Cardiac mortality         
        Model 1 562 101 19.2 68 13.5 0.31 0.71 (0.36–1.39) 
        Model 2        0.84 (0.42–1.68) 
        Model 3§        0.87 (0.41–1.81) 
    Myocardial infarction         
        Model 1 545 137 28.4 67 14 22.9 0.45 0.81 (0.47–1.40) 
        Model 2        0.91 (0.52–1.59) 
        Model 3§        0.98 (0.55–1.75) 
    Stroke         
        Model 1 559 56 11.0 68 10 15.4 0.33 1.40 (0.71–2.74) 
        Model 2        1.75 (0.88–3.45) 
        Model 3§        1.61 (0.79–3.26) 
No family history
Family history
Log-rank P valueHazard ratios (95% CI)
No. patientsNo. eventsAbsolute risk*No. patientsNo. eventsAbsolute risk*
All patients: maternal history         
    All-cause mortality         
        Model 1 1,001 410 43.1 290 81 26.4 <0.001 0.60 (0.48–0.77) 
        Model 2        0.81 (0.64–1.03) 
        Model 3§        0.69 (0.52–0.92) 
    Cardiac mortality         
        Model 1 1,001 172 18.1 290 25 8.2 <0.001 0.45 (0.30–0.69) 
        Model 2        0.61 (0.40–0.93) 
        Model 3§        0.50 (0.31–0.82) 
    Myocardial infarction         
        Model 1 977 227 25.6 281 51 17.9 0.023 0.70 (0.52–0.95) 
        Model 2        0.91 (0.67–1.24) 
        Model 3§        0.73 (0.52–1.03) 
    Stroke         
        Model 1 998 106 11.5 290 26 8.6 0.19 0.75 (0.49–1.15) 
        Model 2        1.00 (0.65–1.54) 
        Model 3§        0.73 (0.45–1.20) 
All patients: paternal history         
    All-cause mortality         
        Model 1 1,159 452 40.3 132 39 28.8 0.039 0.71 (0.51–0.98) 
        Model 2        0.92 (0.66–1.28) 
        Model 3§        1.06 (0.73–1.54) 
    Cardiac mortality         
        Model 1 1,159 184 16.4 132 13 9.6 0.06 0.59 (0.33–1.03) 
        Model 2        0.76 (0.43–1.34) 
        Model 3§        0.96 (0.52–1.78) 
    Myocardial infarction         
        Model 1 1,128 258 24.7 130 20 15.6 0.049 0.64 (0.40–1.00) 
        Model 2        0.79 (0.50–1.25) 
        Model 3§        0.98 (0.60–1.61) 
    Stroke         
        Model 1 1,156 120 11.0 132 12 9.0 0.50 0.81 (0.45–1.47) 
        Model 2        1.10 (0.61–2.00) 
        Model 3§        1.15 (0.60–2.21) 
Women: maternal history         
    All-cause mortality         
        Model 1 495 179 36.9 166 41 22.8 0.004 0.61 (0.44–0.86) 
        Model 2        0.81 (0.58–1.14) 
        Model 3§        0.63 (0.41–0.96) 
    Cardiac mortality         
        Model 1 495 77 15.9 166 10 5.6 0.001 0.35 (0.18–0.68) 
        Model 2        0.47 (0.24–0.91) 
        Model 3§        0.32 (0.14–0.72) 
    Myocardial infarction         
        Model 1 485 104 22.6 161 23 13.7 0.029 0.61 (0.39–0.96) 
        Model 2        0.83 (0.53–1.31) 
        Model 3§        0.45 (0.26–0.76) 
    Stroke         
        Model 1 495 52 11.0 166 14 7.9 0.27 0.72 (0.40–1.30) 
        Model 2        0.93 (0.51–1.67) 
        Model 3§        0.73 (0.40–1.36) 
Women: paternal history         
    All-cause mortality         
        Model 1 597 206 34.5 64 14 20.4 0.047 0.58 (0.34–1.00) 
        Model 2        0.82 (0.48–1.42) 
        Model 3§        1.20 (0.64–2.25) 
    Cardiac mortality         
        Model 1 597 83 13.9 64 5.8 0.08 0.42 (0.15–1.14) 
        Model 2        0.60 (0.22–1.65) 
        Model 3§        0.79 (0.25–2.56) 
    Myocardial infarction         
        Model 1 583 121 21.6 63 9.0 0.032 0.42 (0.19–0.95) 
        Model 2        0.59 (0.26–1.34) 
        Model 3§        0.62 (0.25–1.52) 
    Stroke         
        Model 1 597 64 11.0 64 2.9 0.045 0.26 (0.06–1.07) 
        Model 2        0.37 (0.09–1.50) 
        Model 3§        0.40 (0.10–1.63) 
Men: maternal history         
    All-cause mortality         
        Model 1 506 231 49.6 124 40 31.5 0.006 0.63 (0.45–0.88) 
        Model 2        0.80 (0.57–1.12) 
        Model 3§        0.78 (0.53–1.14) 
    Cardiac mortality         
        Model 1 506 95 20.4 124 15 11.8 0.044 0.58 (0.33–0.99) 
        Model 2        0.74 (0.43–1.29) 
        Model 3§        0.70 (0.39–1.27) 
    Myocardial infarction         
        Model 1 492 123 28.8 120 28 23.9 0.40 0.84 (0.56–1.26) 
        Model 2        0.99 (0.65–1.50) 
        Model 3§        0.92 (0.60–1.42) 
    Stroke         
        Model 1 503 54 12.0 124 12 9.6 0.48 0.80 (0.43–1.49) 
        Model 2        1.07 (0.57–2.01) 
        Model 3§        0.90 (0.47–1.75) 
Men: paternal history         
    All-cause mortality         
        Model 1 562 246 46.7 68 25 37.5 0.30 0.80 (0.53–1.21) 
        Model 2        0.96 (0.63–1.46) 
        Model 3§        1.03 (0.64–1.66) 
    Cardiac mortality         
        Model 1 562 101 19.2 68 13.5 0.31 0.71 (0.36–1.39) 
        Model 2        0.84 (0.42–1.68) 
        Model 3§        0.87 (0.41–1.81) 
    Myocardial infarction         
        Model 1 545 137 28.4 67 14 22.9 0.45 0.81 (0.47–1.40) 
        Model 2        0.91 (0.52–1.59) 
        Model 3§        0.98 (0.55–1.75) 
    Stroke         
        Model 1 559 56 11.0 68 10 15.4 0.33 1.40 (0.71–2.74) 
        Model 2        1.75 (0.88–3.45) 
        Model 3§        1.61 (0.79–3.26) 

*Events per 1,000 person-years.

†Model 1 is unadjusted.

‡Model 2 includes age and sex (where applicable).

§Model 3 includes all variables in the respective most parsimonious models (supplementary Table 1).

Maternal family history, diabetes presentation, and health-related behaviors

To explore possible reasons for a protective effect of a maternal family history, we assessed relationships with diabetes presentation, self-care behaviors, and knowledge of diabetes. No statistical differences were found in mode of presentation at diagnosis (symptomatic or incidental), the nature of the presenting symptoms (thirst, polyuria, fatigue, weight loss, or visual blurring), the frequency of medical visits (family doctors, diabetes clinics, diabetes specialists, diabetes educators, and other medical specialists), or in the performance of self-monitoring of blood glucose. Female patients with either parent having diabetes had higher diabetes knowledge scores than patients without a family history (P ≤ 0.033), but this was not seen in men with a parental family history.

The results of our longitudinal observational study are consistent with those of previous reports in showing that patients with a parental family history of diabetes develop diabetes ∼5 years before their counterparts without a family history (2,,5). We also found that our patients with a maternal family history had worse glycemic control. Despite these unfavorable features, female patients with a maternal family history had a lower risk of myocardial infarction and reduced all-cause and cardiac mortality. Because women with type 2 diabetes have a substantially increased risk of cardiovascular disease compared with nondiabetic women (11), these data suggest that diabetic women with a maternal family history have a risk of myocardial infarction and death that is intermediate between diabetic women without a family history and nondiabetic women. Male patients with a maternal family history and patients of either sex with a paternal family history had outcomes comparable to those in patients without a family history.

In explaining these findings, consideration needs to be given to the relative impact of maternal versus paternal family history on cardiovascular disease in diabetes and why a benefit should be confined to females. Familial disease can be transmitted by genetic and nongenetic inheritance factors. The latter include epigenetic mechanisms such as functional imprinting and nonepigenetic mechanisms such as familial behavioral and cultural effects. With maternal transmission of diabetes, additional mechanisms include intrauterine effects on fetal growth and development that lead to persistent changes in later life and transfer of maternally inherited mitochondrial genes (6,8). The present study included the assessment of a range of biological, lifestyle, and behavioral factors, but we found no candidate explanatory variables among them. Lower baseline systolic blood pressure levels were seen with maternal and paternal family histories, but this effect did not persist after age adjustment. A study in Taiwanese patients found that a parental family history of diabetes conferred a lower risk of hypertension in type 2 diabetes (17), suggesting that further study of blood pressure control in relation to family history would be worthwhile. The women with diabetic parents in the present study had better knowledge of diabetes, but the women with a paternal family history also had greater knowledge without evident benefit, although there is evidence that knowledge alone does not influence cardiovascular outcomes in diabetes (18). Despite these negative findings, we cannot rule out the possibility that behavior related to family history may explain the results. For instance, subjects with a family history may be more likely to recognize the risk factors and symptoms of diabetes and thus receive a diagnosis and start appropriate management (including that for nonglycemic cardiovascular risk factors) at a relatively early stage.

We were not able to collect valid data on the age of onset of diabetes in the mothers, but the great majority are likely to have had type 2 diabetes. Human and animal studies have demonstrated that fetal exposure to maternal diabetes leads to a higher prevalence of impaired glucose tolerance in the offspring largely related to insulin secretory defects (6,8). More than 70% of women with gestational diabetes mellitus develop type 2 diabetes when followed for >10 years, and many women who develop diabetes but had not received a diagnosis of gestational diabetes mellitus are likely to have had some degree of glucose intolerance when pregnant (19,20). Therefore, in the present study, there may have been prenatal changes induced by maternal glucose intolerance in a proportion of patients with maternal family history. Because this mode of transmission of diabetogenic traits is also associated with adverse cardiovascular risk factors in offspring during early life (8,10,21), the present data indicate that there are qualitative differences in the cardiovascular risk that result from prenatal maternal factors compared with that seen in nonfamilial type 2 diabetes. One possible explanation is that fetal diabetogenic factors persist, whereas fetal nonglycemic cardiovascular risk factors wane with age.

There are several potential explanations as to why maternal family history had a differential effect in male and female patients. There are increasing reports of sex differences resulting from genetic and epigenetic transmission in a range of common complex disorders, including cardiovascular disease and type 2 diabetes (8,22). For example, sex differences were reported in an animal model of fetal imprinting in which male offspring developed hypertension, but females were protected (23). It is also possible that men give less accurate family histories, although studies on the analytical validity of family history reports do not indicate a sex bias (24).

The study strengths include the large and representative nature of the sample, the detailed nature of clinical and demographic assessment, and the completeness of ascertainment of the major clinical end points using a well-validated data linkage system. The major limitation relates to the method used to assess family history. Patients classified as having no family history of diabetes included those with limited or no knowledge of the health status of their relatives. This may have led to instances of a false-negative family history and thus an overestimation of the maternal transmission of diabetes because an unknown paternal status is more common in this situation (25). Other potential limitations include recall bias for family history, demonstrated to be minimal in diabetes (24), and a lack of statistical power to detect effects from paternal family history as the number of affected patients was relatively small. We were unable to distinguish gestational diabetes mellitus or the time of onset in the parents with diabetes and the study did not take account of other relevant family history such as having affected siblings.

In summary, the present study demonstrates that women with type 2 diabetes and a maternal family history of diabetes have a lower risk of myocardial infarction and death from cardiac causes than women without a family history of diabetes. These data indicate another source of heterogeneity in the clinical impact of type 2 diabetes and have relevance for understanding the pathophysiology, epidemiology, and public health impact of cardiovascular disease in women with type 2 diabetes.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The Fremantle Diabetes Study was funded by a Raine grant from the University of Western Australia. T.M.E.D. was supported by a National Health and Medical Research Foundation Practitioner Fellowship.

No potential conflicts of interest relevant to this article were reported.

1.
Harrison
TA
,
Hindorff
LA
,
Kim
H
,
Wines
RC
,
Bowen
DJ
,
McGrath
BB
,
Edwards
KL
:
Family history of diabetes as a potential public health tool
.
Am J Prev Med
2003
; 
24
:
152
159
2.
Meigs
JB
,
Cupples
LA
,
Wilson
PW
:
Parental transmission of type 2 diabetes: the Framingham Offspring Study
.
Diabetes
2000
; 
49
:
2201
2207
3.
Mitchell
BD
,
Kammerer
CM
,
Reinhart
LJ
,
Stern
MP
:
NIDDM in Mexican-American families: heterogeneity by age of onset
.
Diabetes Care
1994
; 
17
:
567
573
4.
Bo
S
,
Cavallo-Perin
P
,
Gentile
L
,
Repetti
E
,
Pagano
G
:
Influence of a familial history of diabetes on the clinical characteristics of patients with type 2 diabetes mellitus
.
Diabet Med
2000
; 
17
:
538
542
5.
Molyneaux
L
,
Constantino
M
,
Yue
D
:
Strong family history predicts a younger age of onset for subjects diagnosed with type 2 diabetes
.
Diabetes Obes Metab
2004
; 
6
:
187
194
6.
Dabelea
D
,
Hanson
RL
,
Lindsay
RS
,
Pettitt
DJ
,
Imperatore
G
,
Gabir
MM
,
Roumain
J
,
Bennett
PH
,
Knowler
WC
:
Intrauterine exposure to diabetes conveys risks for type 2 diabetes and obesity: a study of discordant sibships
.
Diabetes
2000
; 
49
:
2208
2211
7.
Alcolado
JC
,
Laji
K
,
Gill-Randall
R
:
Maternal transmission of diabetes
.
Diabet Med
2002
; 
19
:
89
98
8.
Fetita
LS
,
Sobngwi
E
,
Serradas
P
,
Calvo
F
,
Gautier
JF
:
Consequences of fetal exposure to maternal diabetes in offspring (Review)
.
J Clin Endocrinol Metab
2006
; 
91
:
3718
3724
9.
Gong
L
,
Kao
WH
,
Brancati
FL
,
Batts-Turner
M
,
Gary
TL
:
Association between parental history of type 2 diabetes and glycemic control in urban African Americans
.
Diabetes Care
2008
; 
31
:
1773
1776
10.
Gilliam
LK
,
Liese
AD
,
Bloch
CA
,
Davis
C
,
Snively
BM
,
Curb
D
,
Williams
DE
,
Pihoker
C
:
Family history of diabetes, autoimmunity, and risk factors for cardiovascular disease among children with diabetes in the SEARCH for Diabetes in Youth Study
.
Pediatr Diabetes
2007
; 
8
:
354
361
11.
Franco
OH
,
Steyerberg
EW
,
Hu
FB
,
Mackenbach
J
,
Nusselder
W
:
Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease
.
Arch Intern Med
2007
; 
167
:
1145
1151
12.
Bruce
DG
,
Davis
WA
,
Cull
CA
,
Davis
TM
:
Diabetes education and knowledge in patients with type 2 diabetes from the community: the Fremantle Diabetes Study
.
J Diabetes Complications
2003
; 
17
:
82
89
13.
Norman
PE
,
Davis
WA
,
Bruce
DG
,
Davis
TM
:
Peripheral arterial disease and risk of cardiac death in type 2 diabetes: the Fremantle Diabetes Study
.
Diabetes Care
2006
; 
29
:
575
580
14.
Holman
CDJ
,
Bass
AJ
,
Rouse
IL
,
Hobbs
MS
:
Population-based linkage of health records in Western Australia: development of a health services research linked database
.
Aust N Z J Public Health
1999
; 
23
:
453
459
15.
Turner
RC
,
Millns
H
,
Neil
HA
,
Stratton
IM
,
Manley
SE
,
Matthews
DR
,
Holman
HH
:
Risk factors for coronary artery disease in non-insulin dependent diabetes: United Kingdom Prospective Diabetes Study (UKPDS: 23)
.
Br Med J
1998
; 
316
:
823
828
16.
Levy
JC
,
Matthews
DR
,
Hermans
MP
:
Correct homeostasis model assessment (HOMA) evaluation uses the computer program
.
Diabetes Care
1998
; 
21
:
2191
2192
17.
Tseng
CH
:
Effect of parental hypertension and/or parental diabetes on hypertension in Taiwanese diabetic patients
.
Eur J Clin Invest
2007
; 
37
:
870
877
18.
Sánchez
CD
,
Newby
LK
,
McGuire
DK
,
Hasselblad
V
,
Feinglos
MN
,
Ohman
EM
:
Diabetes-related knowledge, atherosclerotic risk factor control, and outcomes in acute coronary syndromes
.
Am J Cardiol
2005
; 
95
:
1290
1294
19.
Kim
C
,
Newton
KM
,
Knopp
RH
:
Gestational diabetes and the incidence of type 2 diabetes: a systematic review
.
Diabetes Care
2002
; 
25
:
1862
1868
20.
Carr
DB
,
Utzschneider
KM
,
Hull
RL
,
Tong
J
,
Wallace
TM
,
Kodama
K
,
Shofer
JB
,
Heckbert
SR
,
Boyko
EJ
,
Fujimoto
WY
,
Kahn
SE
:
Gestational diabetes mellitus increases the risk of cardiovascular disease in women with a family history of type 2 diabetes
.
Diabetes Care
2006
; 
29
:
2078
2083
21.
Choo
KE
,
Lau
KB
,
Davis
WA
,
Chew
PH
,
Jenkins
AJ
,
Davis
TM
:
Cardiovascular risk factors in pre-pubertal Malays: effects of diabetic parentage
.
Diabetes Res Clin Pract
2007
; 
76
:
119
125
22.
Assimes
TL
,
Knowles
JW
,
Basu
A
,
Iribarren
C
,
Southwick
A
,
Tang
H
,
Absher
D
,
Li
J
,
Fair
JM
,
Rubin
GD
,
Sidney
S
,
Fortmann
SP
,
Go
AS
,
Hlatky
MA
,
Myers
RM
,
Risch
N
,
Quertermous
T
:
Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study
.
Hum Mol Genet
2008
; 
17
:
2320
2328
23.
Ojeda
NB
,
Grigore
D
,
Robertson
EB
,
Alexander
BT
:
Estrogen protects against increased blood pressure in postpubertal female growth restricted offspring
.
Hypertension
2007
; 
50
:
679
685
24.
Kahn
LB
,
Marshall
JA
,
Baxter
J
,
Shetterly
SM
,
Hamman
RF
:
Accuracy of reported family history of diabetes mellitus: results from San Luis Valley Diabetes Study
.
Diabetes Care
1990
; 
13
:
796
798
25.
Thorand
B
,
Liese
AD
,
Metzger
MH
,
Reitmeir
P
,
Schneider
A
,
Löwel
H
:
Can inaccuracy of reported parental history of diabetes explain the maternal transmission hypothesis for diabetes?
Int J Epidemiol
2001
; 
30
:
1084
1089
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

Supplementary data